Pharmacological treatment of negative symptoms of schizophrenia

Therapeutic opportunity or Cul-de-sac?

Peter F Buckley, S. M. Stahl

Research output: Contribution to journalReview article

113 Citations (Scopus)

Abstract

Objective: Negative symptoms of schizophrenia are debilitating and they contribute to poor outcome in schizophrenia. Initial enthusiasm that second-generation antipsychotics would prove to be powerful agents to improve negative symptoms has given way to relative pessimism that the effects of current pharmacological treatments are at best modest. Method: A review of the current 'state-of-play' of pharmacological treatments for negative symptoms in schizophrenia. Results: Treatment results to date have been largely disappointing. The evidence for efficacy of second-generation antipsychotics is reviewed. Conclusion: The measurement and treatment trials methodology for the evaluation of negative symptoms need additional refinement before therapeutic optimism that better treatments for negative symptoms can be realized.

Original languageEnglish (US)
Pages (from-to)93-100
Number of pages8
JournalActa Psychiatrica Scandinavica
Volume115
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

Schizophrenia
Pharmacology
Antipsychotic Agents
Symptom Assessment
Therapeutics
Pessimism
Optimism

Keywords

  • Antipsychotic medications
  • Measurement
  • Negative symptoms

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Pharmacological treatment of negative symptoms of schizophrenia : Therapeutic opportunity or Cul-de-sac? / Buckley, Peter F; Stahl, S. M.

In: Acta Psychiatrica Scandinavica, Vol. 115, No. 2, 01.02.2007, p. 93-100.

Research output: Contribution to journalReview article

@article{caa0f7a046de490891d42bdd466070a5,
title = "Pharmacological treatment of negative symptoms of schizophrenia: Therapeutic opportunity or Cul-de-sac?",
abstract = "Objective: Negative symptoms of schizophrenia are debilitating and they contribute to poor outcome in schizophrenia. Initial enthusiasm that second-generation antipsychotics would prove to be powerful agents to improve negative symptoms has given way to relative pessimism that the effects of current pharmacological treatments are at best modest. Method: A review of the current 'state-of-play' of pharmacological treatments for negative symptoms in schizophrenia. Results: Treatment results to date have been largely disappointing. The evidence for efficacy of second-generation antipsychotics is reviewed. Conclusion: The measurement and treatment trials methodology for the evaluation of negative symptoms need additional refinement before therapeutic optimism that better treatments for negative symptoms can be realized.",
keywords = "Antipsychotic medications, Measurement, Negative symptoms",
author = "Buckley, {Peter F} and Stahl, {S. M.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1111/j.1600-0447.2007.00992.x",
language = "English (US)",
volume = "115",
pages = "93--100",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Pharmacological treatment of negative symptoms of schizophrenia

T2 - Therapeutic opportunity or Cul-de-sac?

AU - Buckley, Peter F

AU - Stahl, S. M.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Objective: Negative symptoms of schizophrenia are debilitating and they contribute to poor outcome in schizophrenia. Initial enthusiasm that second-generation antipsychotics would prove to be powerful agents to improve negative symptoms has given way to relative pessimism that the effects of current pharmacological treatments are at best modest. Method: A review of the current 'state-of-play' of pharmacological treatments for negative symptoms in schizophrenia. Results: Treatment results to date have been largely disappointing. The evidence for efficacy of second-generation antipsychotics is reviewed. Conclusion: The measurement and treatment trials methodology for the evaluation of negative symptoms need additional refinement before therapeutic optimism that better treatments for negative symptoms can be realized.

AB - Objective: Negative symptoms of schizophrenia are debilitating and they contribute to poor outcome in schizophrenia. Initial enthusiasm that second-generation antipsychotics would prove to be powerful agents to improve negative symptoms has given way to relative pessimism that the effects of current pharmacological treatments are at best modest. Method: A review of the current 'state-of-play' of pharmacological treatments for negative symptoms in schizophrenia. Results: Treatment results to date have been largely disappointing. The evidence for efficacy of second-generation antipsychotics is reviewed. Conclusion: The measurement and treatment trials methodology for the evaluation of negative symptoms need additional refinement before therapeutic optimism that better treatments for negative symptoms can be realized.

KW - Antipsychotic medications

KW - Measurement

KW - Negative symptoms

UR - http://www.scopus.com/inward/record.url?scp=33846297688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846297688&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0447.2007.00992.x

DO - 10.1111/j.1600-0447.2007.00992.x

M3 - Review article

VL - 115

SP - 93

EP - 100

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

IS - 2

ER -